The identification not only of RET mutations in tumor tissue, but also of predictive indicators for the efficacy of PRRT, for example CCK2R and SSTR2 imaging, will likely be of great importance for the choice of the most appropriate therapy of MTC on an individual level. The gene discussed is SSTR2; the disease is medullary thyroid gland carcinoma.